Información de EyePoint Pharmaceuticals Inc, dividendo de EyePoint Pharmaceuticals Inc, actividades de los accionistas y más

Más Datos de EyePoint Pharmaceuticals Inc Compañía

EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.

Información de EyePoint Pharmaceuticals Inc



Símbolo de cotizaciónEYPT

Nombre de la empresaEyePoint Pharmaceuticals Inc

Fecha de salida a bolsaJan 27, 2005

Director ejecutivoDuker (Jay S)

Número de empleados165

Tipo de seguridadOrdinary Share

Fin del año fiscalJan 27

Dirección480 Pleasant Street, Suite C400

CiudadWATERTOWN

Bolsa de valoresNASDAQ OMX - NASDAQ BASIC

PaísUnited States of America

Código postal02472

Teléfono16179265000

Sitio Webhttps://eyepointpharma.com/

Símbolo de cotizaciónEYPT

Fecha de salida a bolsaJan 27, 2005

Director ejecutivoDuker (Jay S)

Ejecutivos de EyePoint Pharmaceuticals Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Jay S. Duker, M.D.

President, Chief Executive Officer, Director

753.40K

+67787.00%

Ms. Nancy S. Lurker

Executive Vice Chairman of the Board

653.26K

+87799.00%

Dr. John B. Landis, Ph.D.

Non-Executive Independent Director

142.86K

+121464.00%

Ms. Karen L. Zaderej

Non-Executive Independent Director

117.28K

+2000.00%

Mr. Stuart Duty

Non-Executive Independent Director

45.01K

+45014.00%

Mr. Ramiro Ribeiro, M.D., Ph.D.

Chief Medical Officer

39.06K

--

Dr. Goeran A. Ando, M.D.

Non-Executive Independent Chairman of the Board

--

Ms. Wendy F. Dicicco, CPA

Non-Executive Independent Director

--

Mr. George Elston

Chief Financial Officer, Executive Vice President

--

Mr. Stern

Investor Relations

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Jay S. Duker, M.D.

President, Chief Executive Officer, Director

753.40K

+67787.00%

Ms. Nancy S. Lurker

Executive Vice Chairman of the Board

653.26K

+87799.00%

Dr. John B. Landis, Ph.D.

Non-Executive Independent Director

142.86K

+121464.00%

Ms. Karen L. Zaderej

Non-Executive Independent Director

117.28K

+2000.00%

Mr. Stuart Duty

Non-Executive Independent Director

45.01K

+45014.00%

Mr. Ramiro Ribeiro, M.D., Ph.D.

Chief Medical Officer

39.06K

--

Desglose de ingresos

Divisa: USDActualizado: mar., 6 de ene

FY2024

FY2023

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

Por negocioUSD

Nombre

Ganancia

Proporción

YUTIQ

3.10M

7.16%

Por regiónUSD

Nombre

Ganancia

Proporción

United States

42.05M

97.17%

China

1.12M

2.60%

United Kingdom

100.00K

0.23%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

YUTIQ

3.10M

7.16%

Estadísticas de accionistas

Actualizado: lun., 17 de nov

Accionistas

Tipos de accionistas

Accionistas

Proporción

Cormorant Asset Management, LP

9.98%

Suvretta Capital Management, LLC

7.48%

Adage Capital Management, L.P.

6.72%

The Vanguard Group, Inc.

5.82%

BlackRock Institutional Trust Company, N.A.

5.17%

Otro

64.82%

Accionistas

Proporción

Cormorant Asset Management, LP

9.98%

Suvretta Capital Management, LLC

7.48%

Adage Capital Management, L.P.

6.72%

The Vanguard Group, Inc.

5.82%

BlackRock Institutional Trust Company, N.A.

5.17%

Otro

64.82%

Tipos de accionistas

Accionistas

Proporción

Hedge Fund

32.77%

Investment Advisor

25.06%

Investment Advisor/Hedge Fund

20.85%

Research Firm

4.43%

Private Equity

3.39%

Individual Investor

2.96%

Venture Capital

2.58%

Bank and Trust

1.06%

Pension Fund

0.13%

Otro

6.78%

Participación institucional



Actualizado: lun., 8 de dic

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q4

363

69.86M

126.07%

--

2025Q3

373

69.94M

127.01%

+1.23K

2025Q2

381

69.95M

127.71%

-5.27M

2025Q1

371

75.32M

126.89%

-11.89M

2024Q4

359

75.24M

109.81%

+11.20M

2024Q3

343

59.71M

126.62%

+193.11K

2024Q2

330

60.06M

120.79%

+1.75M

2024Q1

313

56.72M

108.78%

+2.51M

2023Q4

268

50.21M

76.86%

+16.41M

2023Q3

224

33.81M

98.97%

+2.98M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

Cormorant Asset Management, LP

8.27M

9.98%

-60.00K

-0.72%

Dec 04, 2025

Suvretta Capital Management, LLC

6.19M

7.48%

-611.38K

-8.99%

Sep 30, 2025

Adage Capital Management, L.P.

5.56M

6.72%

-1.24M

-18.24%

Sep 30, 2025

The Vanguard Group, Inc.

3.79M

4.58%

-8.13K

-0.21%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

4.28M

5.17%

-316.39K

-6.88%

Sep 30, 2025

Franklin Advisers, Inc.

4.14M

5%

-130.85K

-3.07%

Sep 30, 2025

Federated Hermes Global Investment Management Corp.

3.58M

4.32%

-1.46K

-0.04%

Sep 30, 2025

TCG Crossover Management, LLC

3.57M

4.32%

--

Sep 30, 2025

Citadel Advisors LLC

2.14M

2.58%

-208.82K

-8.91%

Sep 30, 2025

Paradigm BioCapital Advisors LP

2.01M

2.42%

+2.01M

--

Sep 30, 2025

ETFs relacionados



Actualizado: sáb., 6 de dic

Nombre

Proporción

Virtus LifeSci Biotech Clinical Trials ETF

1%

Simplify Health Care ETF

0.99%

State Street SPDR S&P Pharmaceuticals ETF

0.98%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

0.95%

Invesco Dorsey Wright SmallCap Momentum ETF

0.36%

Federated Hermes MDT Small Cap Core ETF

0.3%

iShares Micro-Cap ETF

0.15%

iShares Health Innovation Active ETF

0.15%

ProShares Ultra Nasdaq Biotechnology

0.12%

Invesco Nasdaq Biotechnology ETF

0.09%

Virtus LifeSci Biotech Clinical Trials ETF

Proporción1%

Simplify Health Care ETF

Proporción0.99%

State Street SPDR S&P Pharmaceuticals ETF

Proporción0.98%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

Proporción0.95%

Invesco Dorsey Wright SmallCap Momentum ETF

Proporción0.36%

Federated Hermes MDT Small Cap Core ETF

Proporción0.3%

iShares Micro-Cap ETF

Proporción0.15%

iShares Health Innovation Active ETF

Proporción0.15%

ProShares Ultra Nasdaq Biotechnology

Proporción0.12%

Invesco Nasdaq Biotechnology ETF

Proporción0.09%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Fecha ex-dividendo

Tipo

Relación

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Fecha

Fecha ex-dividendo

Tipo

Relación

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1